# A Study of Tucatinib and Trastuzumab in People With Rectal Cancer

Source: https://onco.cc/trials/nct05672524/  
OnCo record `nct05672524` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of trastuzumab and tucatinib in colorectal cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.

## Summary

A Study of Tucatinib and Trastuzumab in People With Rectal Cancer is a phase 2, interventional study registered as NCT05672524 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 37 participants, started 2022-12-30 and due to reach its primary completion in 2027-07-30. Interventions recorded: Trastuzumab; Tucatinib. Conditions listed: Adenocarcinoma of the Rectum; Locally Advanced Rectal Adenocarcinoma; Rectal Adenocarcinoma; HER2 Positive Rectal Adenocarcinoma; Rectal Cancer. Primary outcome: Clinical complete response of study participants. Colorectal eligibility wording from the registry: "* Histologically confirmed rectal adenocarcinoma". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05672524
- Phase: 2
- Setting: A Phase II Study of Induction Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma
- Sponsor: Memorial Sloan Kettering Cancer Center
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT05672524: https://clinicaltrials.gov/study/NCT05672524

## Connected records

- cancers: [HER2-amplified colorectal cancer](https://onco.cc/cancers/her2-amplified-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [HER2 tyrosine kinase inhibitors](https://onco.cc/technologies/her2-tyrosine-kinase-inhibitors/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/), [Tucatinib](https://onco.cc/drugs/tucatinib/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05672524.json